VIEWPOINTS


Viewpoints are a collection of news and opinion articles that capture key research developments and important issues in the field of oncology.


ThromboSeq and Tumor-educated Platelets for Lung Cancer Detection

ThromboSeq and Tumor-educated Platelets for Lung Cancer Detection

The thromboSeq test result might not only provide information regarding lung cancer diagnostics, but potentially any other tumor types as well, and may enable tumor-type stratification.

Treatment Considerations for Older Patients With Lymphoma

Treatment Considerations for Older Patients With Lymphoma

As patients become older, additional factors must be considered in planning their treatment.

Paths Forward for Confronting Extramedullary Multiple Myeloma

Paths Forward for Confronting Extramedullary Multiple Myeloma

Extramedullary multiple myeloma is increasingly encountered in the clinic and most patients will need aggressive treatment.

Multigene Test May Help Identify Hereditary Kidney Cancers

Multigene Test May Help Identify Hereditary Kidney Cancers

Hereditary kidney cancer syndromes are often diagnosed by astute clinicians who recognize that there is more to a patient's diagnosis then just the random event of getting cancer.

Tumor Re-Biopsy May Be Best Option to Identify Cause of EGFR-TKI Resistance in NSCLC

Tumor Re-Biopsy May Be Best Option to Identify Cause of EGFR-TKI Resistance in NSCLC

Not conducting a second tissue biopsy could have dangerous implications for the patient according to a recent article.

Virotherapy for Multiple Myeloma: The Current State of Research

Virotherapy for Multiple Myeloma: The Current State of Research

An emerging approach in the early stages of clinical development for MM is oncolytic virotherapy, in which viruses are used to eliminate cancer cells directly or indirectly.

Sirolimus Use in Graft Versus Host Disease

Sirolimus Use in Graft Versus Host Disease

As more experience with sirolimus has been gained, it began to be used "off-label" to prevent rejection in multiple transplant recipients and is now being studied in the treatment of GVHD.

Knowledge of Immunotherapies in Melanoma Continues to Grow

Knowledge of Immunotherapies in Melanoma Continues to Grow

Clinicians continue to learn about which patients will benefit most from different immunotherapy treatments, and how dosing can effect adverse events.

Telomere Length May Predict Renal Cell Carcinoma Risk in Patients with VHL

Telomere Length May Predict Renal Cell Carcinoma Risk in Patients with VHL

There are estimated to be 13 distinct hereditary renal cell carcinoma (RCC) syndromes, each of which is associated with specific germline mutations, including von Hippel-Lindau disease (VHL).

Identifying Frail Patients With Multiple Myeloma Improves Treatment Selection

Identifying Frail Patients With Multiple Myeloma Improves Treatment Selection

Clinicians can use a geriatric assessment for an objective appraisal of the health status of older patients with multiple myeloma.

Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths

Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths

Does the failure of pembrolizumab in multiple myeloma clinical trials imply checkpoint inhibition is unlikely to work for patients with the disease?

In Focus: Axitinib for Metastatic Renal Cell Carcinoma

In Focus: Axitinib for Metastatic Renal Cell Carcinoma

Axitinib is an efficacious drug among patients with metastatic RCC, though selecting the appropriate patients for treatment and the correct dose can be difficult.

Telotristat for Diarrhea in Patients With Carcinoid Syndrome

Telotristat for Diarrhea in Patients With Carcinoid Syndrome

Telotristat represents a new treatment option that may decrease diarrhea incidence with a relatively safe side effect profile.

Study Predicts Important Role for SABR in Treatment of Early-stage NSCLC

Study Predicts Important Role for SABR in Treatment of Early-stage NSCLC

SABR may be used to improve PFS, or potentially OS, among patients who have a good response to chemotherapy, targeted therapy, or immunotherapy.

Immune-mediated Hepatitis: Challenges in Management

Immune-mediated Hepatitis: Challenges in Management

The incidence of immune-mediated hepatitis in patients receiving immunotherapy varies based on the agent and other concomitant medications, though it is not uncommon.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters